Compare SANG & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SANG | ALXO |
|---|---|---|
| Founded | 1984 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 157.1M | 172.8M |
| IPO Year | 2018 | 2020 |
| Metric | SANG | ALXO |
|---|---|---|
| Price | $4.66 | $1.24 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $5.54 | $4.60 |
| AVG Volume (30 Days) | 127.9K | ★ 1.5M |
| Earning Date | 11-13-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 26.36 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3.23 | N/A |
| Revenue Next Year | $0.96 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.40 | $0.86 |
| 52 Week High | $5.42 | $2.66 |
| Indicator | SANG | ALXO |
|---|---|---|
| Relative Strength Index (RSI) | 58.43 | 47.68 |
| Support Level | $4.64 | $0.86 |
| Resistance Level | $5.02 | $1.30 |
| Average True Range (ATR) | 0.11 | 0.15 |
| MACD | -0.05 | 0.04 |
| Stochastic Oscillator | 44.74 | 75.97 |
Sangoma Technologies Corp is a provider of hardware and software components that enable or enhance Internet Protocol Communications Systems for both telecom and datacom applications. It is engaged in the development, manufacturing, distribution, and support of voice and data connectivity components for software-based communication applications. Its product includes data and telecom boards for media and signal processing, as well as gateway appliances and software. The Company sells into two geographic location USA and Other countries. Key revenue is generated from USA.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.